<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589329</url>
  </required_header>
  <id_info>
    <org_study_id>IRB01-00012</org_study_id>
    <nct_id>NCT00589329</nct_id>
  </id_info>
  <brief_title>Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam</brief_title>
  <official_title>Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth remains a major health concern affecting up to 12% of all live births prior to
      37 weeks gestation. As preterm birth can often be associated with infection our proposal is
      to evaluate in a randomized fashion antibiotics for women with advanced cervical exams.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm birth, its causes, prevention, complications and ramifications persist as an
      important focus of obstetrical research. In the United States 11.8% of all live births occur
      prior to 37 weeks gestation. As many as 45% of these deliveries will have been proceeded by
      preterm labor with intact membranes.(2) Both preterm labor and preterm premature rupture of
      membranes have both been associated with evidence intrauterine infection. While antibiotic
      treatment in conservative management of preterm PROM remote from term has been shown to
      significantly prolong pregnancy and reduce infant morbidity, (16) data regarding the
      effectiveness of antibiotics for pregnancy prolongation in preterm labor are inconsistent.
      (3-15) Currently, narrow spectrum antibiotics (penicillin or clindamycin) are given prior to
      delivery to reduce the risk of neonatal Group B Beta Streptococcus (GBS) sepsis, however
      broad spectrum antibiotic treatment of women with preterm labor for pregnancy prolongation is
      not recommended.

      Review of the literature regarding antibiotic treatment for pregnancy prolongation in preterm
      labor reveals that most studies utilized single agent therapy, and no study has evaluated the
      use of antibiotics for pregnancy prolongation in women with an advanced cervical exam (&gt;4cm).
      While a number of studies have shown significant pregnancy prolongation in unselected
      populations,(5,12,13) only one study of 12 reviewed was able to show a neonatal benefit to
      adjunctive antibiotic use.(12,20) Norman, et al was able to show a reduction in the incidence
      of necrotising enterocolitis with the use of antibiotics. Given the number of studies in this
      area, and the lack of supporting evidence, this likely represents an alpha error. Another
      study by Svare et al was able to show a significant decrease in NICU admissions for women
      treated with antibiotics in the setting of preterm labor, however no change was reported in
      neonatal morbidities.

      Our proposed study is designed to evaluate patients at particular risk for preterm delivery;
      those with advanced cervical exam. In this randomized prospective controlled study, we intend
      to examine the influence of adjunctive antibiotic use in preterm labor complicated by a
      cervical exam of 4 cm or greater. We plan to compare a study group receiving broad-spectrum
      antibiotics with a control group that will not receive antibiotics for pregnancy
      prolongation. Both groups will receive antibiotics for GBS prophylaxis as indicated. We hope
      to see a delay in delivery in the study group as a primary outcome. Secondary outcomes will
      include the use of steroids, neonatal complications including sepsis, intraventricular
      hemorrhage, periventricular leukomalacea, mechanical ventilation and respiratory distress
      syndrome, retinopathy of prematurity and necrotizing enterocolitis, and neonatal ICU stay.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    published data suggest potential harm in other investigations.
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Pregnancy Prolongation</measure>
    <time_frame>Measured from randomization to delivery in hours</time_frame>
    <description>The length of time (in hours) from initiation of therapy to delivery will establish the latency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Distress</measure>
    <time_frame>newborn nursery</time_frame>
    <description>Respiratory distress will be defined by the clinical record documentation of the neonatal team.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Length of Pregnancy Prolongation in Hours</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>roup A will be assigned to receive antibiotics:
Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythromycin and metronidazole (antibiotics)</intervention_name>
    <description>Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>IV and pill placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients admitted with the diagnosis of preterm labor between 24 0/7 and 33 6/7
             weeks gestation. Preterm labor will be defined by regular contractions and/or cervical
             change from last documented exam.

          2. Cervical exam 4 cm or greater

          3. Intact membranes

        Exclusion Criteria:

          1. Multiple gestation (&gt;2)

          2. Clinical evidence of chorioamnionitis, such as maternal fever, uterine tenderness,
             fetal tachycardia

          3. Lethal fetal anomaly

          4. Persistent vaginal bleeding, abruption, or placenta previa

          5. Rupture of membranes

          6. Maternal illness or fetal indication requiring delivery

          7. Inability to give informed consent

          8. Serious allergy to study medications. GI discomfort will not be considered a drug
             allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Mercer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center MFM Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thaddeus Waters, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <results_first_submitted>May 22, 2018</results_first_submitted>
  <results_first_submitted_qc>August 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Ted Waters</investigator_full_name>
    <investigator_title>MFM attending, metroheatlh</investigator_title>
  </responsible_party>
  <keyword>Preterm birth</keyword>
  <keyword>antibiotics</keyword>
  <keyword>preterm labor</keyword>
  <keyword>respiratory distress</keyword>
  <keyword>pergnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Group A will be assigned to receive antibiotics:
Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days.
erythromycin and metronidazole (antibiotics): Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
placebo: IV and pill placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Antibiotic group</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Non antibiotic group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Pregnancy Prolongation</title>
        <description>The length of time (in hours) from initiation of therapy to delivery will establish the latency</description>
        <time_frame>Measured from randomization to delivery in hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A will be assigned to receive antibiotics:
Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days.
erythromycin and metronidazole (antibiotics): Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
placebo: IV and pill placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Pregnancy Prolongation</title>
          <description>The length of time (in hours) from initiation of therapy to delivery will establish the latency</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="36"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Distress</title>
        <description>Respiratory distress will be defined by the clinical record documentation of the neonatal team.</description>
        <time_frame>newborn nursery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>roup A will be assigned to receive antibiotics:
Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days.
erythromycin and metronidazole (antibiotics): Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
placebo: IV and pill placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Distress</title>
          <description>Respiratory distress will be defined by the clinical record documentation of the neonatal team.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>roup A will be assigned to receive antibiotics:
Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days.
erythromycin and metronidazole (antibiotics): Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
placebo: IV and pill placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Larraine Presley</name_or_title>
      <organization>MetroHealth Medical CEnter</organization>
      <phone>216-778-8927</phone>
      <email>lpresley@metrohealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

